Companies · Biotechnology

OXOS Series #7 Holdings, LLC

ATLANTA · Biotechnology

Diligence memoA one-page analyst read on OXOS Series #7 Holdings, LLC — recommendation, valuation, rhythm, risks.
$7.8M
Total raised · real
1
Rounds
0.2×
Latest step-up
Top 50%
Sector rank · raised
Series A
Latest stage · inferred · Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

OXOS Series #7 Holdings, LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.91× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.4 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

OXOS Series #7 Holdings, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
4.4 yr record
Peak capital year was 2022 with $9.6M across 2 filings.
Market position
ahead of 51% of Biotechnology peers
Capital scale is ahead of 51% of Biotechnology peers; modeled value is above 63% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2022: $9.6M across 2 filings.
  • Largest single filing was $7.8M on 2022-02-08.
  • Filing rows sum to $9.6M, while canonical raised total is $7.8M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

OXOS Series #7 Holdings, LLC is one of 4293 Biotechnology companies tracked from ATLANTA. By capital raised it ranks mid-pack (ahead of 51% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
23
Investors (latest)
2022
Year incorporated
2022-02-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2022-02-08 Raised $7.8M (real) Modeled valuation $129M (est)$7.8M$129MSeries A2022Seed · 2022-02-08 Raised $1.8M (real) Modeled valuation $34M (est)$1.8M$34MSeed2022+$1.8MCumulative $9.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$7.8M · 2022
Bridge · Series A-stage$1.8M · 2022smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$129.2M
Base estimate est.
$8.5M
Conservative case
$485.1M
Upside case
$35.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $129.2M · 2022-02-082022Seed · modeled $33.7M · 2022-02-082022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
4.4 yr
Elapsed time used
4.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
4.4 yr
On record since
2022
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$7.8M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.3× of median
This company$1.8M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.0× above median
This company$129.2M
Sector median$64.2M

Raised more than 51% of sector peers (real $). Modeled value above 63% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #27 of 303.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)OXOS Series #7 Holdings, LLC (this company) Raised $7.8M · modeled $129.2M (est)OXOS Series #7 Holdings, LLC
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
OXOS Series #7 Holdings, LLC this companySeries A$7.8M$129.2M2.91×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$7.8M2022-02-08$35.2M$129.2M90%
Seed$1.8M2022-02-08$9.2M$33.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$7.8M2022-02-08
    • First recorded raise — entered as Series A.
    • 79 investors on this round.
  2. Seed$1.8M2022-02-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.2× smaller than the prior — bridge or down round.
    • 23 investors on this round.
Intelligence
Modeled next raise
$1.8M
Modeled next size est.range $1.8M$3.0M
0.2×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Joshua Hix2 other2022-02
Registry & provenance

OXOS Series #7 Holdings, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1922447
SEC CIK
2022
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
pHLIP, Inc.BiotechnologySeries A$7.9M$159.5Msame sector · same stage
PharmaTher Holdings Ltd.BiotechnologySeries A$7.9M$156.6Msame sector · same stage
Profluent Bio Inc.BiotechnologySeries A$8.0M$103.4Msame sector · same stage
Proteogenix IncBiotechnologySeries A$8.0M$144.6Msame sector · same stage
Akriveia Therapeutics, LLCBiotechnologySeries A$7.5M$108.5Msame sector · same stage
Xyone Therapeutics, Inc.BiotechnologySeries A$7.5M$143.2Msame sector · same stage
Bio-Tech Medical Software, Inc.BiotechnologySeries A$8.2M$133.2Msame sector · same stage
Viral Logic Systems Technology CorpBiotechnologySeries A$8.4M$121.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
OXOS Series #6 Holdings, LLCBiotechnologySeries A$119.2M95%
Seventh Sense Biosystems, Inc.BiotechnologySeries B$732.6M87%
Lab7 Systems, Inc.BiotechnologySeed$66.6M86%
Akouos, Inc.BiotechnologySeries D+$4.3B86%
BioHSV Holdings, Inc.BiotechnologySeed$33.5M86%
GRO Biosciences Inc.BiotechnologySeries B$191.9M85%
BioVaxys Technology Corp.BiotechnologyPre-Seed$7.2M85%
JoJo Biotechnologies Co LtdBiotechnologySeries A$17.6M85%
Frequently asked
How much funding has OXOS Series #7 Holdings, LLC raised?
OXOS Series #7 Holdings, LLC has raised approximately $7.8M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is OXOS Series #7 Holdings, LLC's estimated valuation?
Provath's modeled valuation for OXOS Series #7 Holdings, LLC is approximately $129.2M (modeled range $8.5M–$485.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is OXOS Series #7 Holdings, LLC at?
OXOS Series #7 Holdings, LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Feb 08.
What does OXOS Series #7 Holdings, LLC do and where is it based?
OXOS Series #7 Holdings, LLC operates in the Biotechnology sector, based in ATLANTA.
Explore related

See where OXOS Series #7 Holdings, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at OXOS Series #7 Holdings, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.